Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2011, Article ID 659769, 5 pages
http://dx.doi.org/10.1155/2011/659769
Case Report

Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases

1Infectious Disease Division, Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103-2714, USA
2Infectious Disease Division, Department of Medicine, New York Hospital Queens, Flushing, NY 11355, USA
3Infectious Disease Division, Department of Medicine, VA New Jersey Health Care System, 385 Tremont Avenue, 111-ID, East Orange, NJ 07018, USA

Received 9 August 2011; Revised 11 September 2011; Accepted 12 September 2011

Academic Editor: Florian Thalhammer

Copyright © 2011 Eric Gomez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Rosenblatt, “Laboratory tests used to guide antimicrobial therapy,” Mayo Clinic Proceedings, vol. 58, no. 1, pp. 14–20, 1983. View at Google Scholar · View at Scopus
  2. A. Robinson, R. C. Barlett, and M. F. Mazens, “Antimicrobial synergy testing based on antibiotic levels, minimal bactericidal concentration, and serum bactericidal activity,” American Journal of Clinical Pathology, vol. 84, no. 3, pp. 328–333, 1985. View at Google Scholar · View at Scopus
  3. E. B. Hirsch and V. H. Tam, “Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 6, pp. 1119–1125, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. Endimiani, G. Patel, K. M. Hujer et al., “In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 526–529, 2010. View at Publisher · View at Google Scholar · View at PubMed
  5. J. J. Rahal, “Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species,” Clinical Infectious Diseases, vol. 43, supplement 2, pp. S95–S99, 2006. View at Publisher · View at Google Scholar · View at PubMed
  6. Institute CCaLS, Methodology for the Serum Bactericidal Test. Approved Guidelines, CLSI, Wayne, Pa, USA, 2009.
  7. N. Petrosillo, E. Ioannidou, and M. E. Falagas, “Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies,” Clinical Microbiology and Infection, vol. 14, no. 9, pp. 816–827, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. Li, C. R. Rayner, R. L. Nation et al., “Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 9, pp. 2946–2950, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Yoon, C. Urban, C. Terzian, N. Mariano, and J. J. Rahal, “In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant acinetobacter baumannii,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 3, pp. 753–757, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Thiolas, C. Bollet, B. La Scola, D. Raoult, and J.-M. Pages, “Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 4, pp. 1354–1358, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. J. Lee, G. Patel, S. Huprikar, D. P. Calfee, and S. G. Jenkins, “Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumonia infection,” Journal of Clinical Microbiology, vol. 47, no. 5, pp. 1611–1612, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. Pournaras, G. Vrioni, E. Neou et al., “Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay,” International Journal of Antimicrobial Agents, vol. 37, no. 3, pp. 244–247, 2011. View at Publisher · View at Google Scholar · View at PubMed
  13. C. Urban, N. Mariano, and J. J. Rahal, “In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2732–2734, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. Elemam, J. Rahimian, and M. Doymaz, “In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae,” Journal of Clinical Microbiology, vol. 48, no. 10, pp. 3558–3562, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. M. Humphries, T. Kelesidis, J. D. Bard, K. W. Ward, D. Bhattacharya, and M. A. Lewinski, “Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin,” Journal of Medical Microbiology, vol. 59, part 11, pp. 1383–1386, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. C. C. Bulik and D. P. Nicolau, “In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 10, pp. 4112–4115, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. Landman, C. Georgescu, D. A. Martin, and J. Quale, “Polymyxins revisited,” Clinical Microbiology Reviews, vol. 21, no. 3, pp. 449–465, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. Klastersky, D. Daneau, G. Swings, and D. Weerts, “Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections,” The Journal of Infectious Diseases, vol. 129, no. 2, pp. 187–193, 1974. View at Google Scholar · View at Scopus
  19. C. W. Stratton, “The role of the microbiology laboratory in the treatment of infective endocarditis,” Journal of Antimicrobial Chemotherapy, vol. 20, supplement A, pp. 41–49, 1987. View at Google Scholar
  20. B. S. Schwartz, P. D. Ngo, and B. J. Guglielmo, “Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding?” Annals of Pharmacotherapy, vol. 42, no. 2, pp. 289–290, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. A. F. Viollier, H. C. Standiford, G. L. Drusano et al., “Comparative pharmacokinetics and serum bactericidal activity of mezlocillin, ticarcillin and piperacillin, with and without gentamicin,” Journal of Antimicrobial Chemotherapy, vol. 15, no. 5, pp. 597–606, 1985. View at Google Scholar
  22. P. Van der Auwera, A. Vandermies, S. Lieppe, P. Grenier, A. M. Bourguignon, and F. Ernst, “Ceftazidime combined with mecillinam: serum bactericidal titres compared with in-vitro synergy against gram-negative bacilli,” Journal of Antimicrobial Chemotherapy, vol. 21, no. 6, pp. 745–753, 1988. View at Google Scholar · View at Scopus
  23. J. H. Licht, “Penicillinase-resistant penicillin/gentamicin synergism. Effect in patients with Staphylococcus aureus bacteremia,” Archives of Internal Medicine, vol. 139, no. 10, pp. 1094–1098, 1979. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Martino, M. Venditti, B. Valente et al., “Serum bactericidal activity as a therapeutic guide in severely granulocytopenic patients with gram-negative septicemia,” European Journal of Cancer and Clinical Oncology, vol. 21, no. 4, pp. 439–445, 1985. View at Google Scholar
  25. M. P. Weinstein, C. W. Stratton, A. Ackley et al., “Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis,” The American Journal of Medicine, vol. 78, no. 2, pp. 262–269, 1985. View at Google Scholar · View at Scopus
  26. C. G. Prober and A. S. Yeager, “Use of the serum bactericidal titer to assess the adequacy of oral antibiotic therapy in the treatment of acute hematogenous osteomyelitis,” The Journal of Pediatrics, vol. 95, no. 1, pp. 131–135, 1979. View at Google Scholar · View at Scopus
  27. P. Cahen, M. Le Bourgeois, C. Delacourt et al., “Serum bactericidal test as a prognostic indicator in acute pulmonary exacerbations of cystic fibrosis,” Pediatrics, vol. 91, no. 2, pp. 451–455, 1993. View at Google Scholar · View at Scopus
  28. J. G. Schlichter, L. H. Mac, and A. Milzer, “Effective penicillin therapy in subacute bacterial endocarditis and other chronic infections,” The American Journal of the Medical Sciences, vol. 217, no. 6, pp. 600–608, 1949. View at Google Scholar
  29. P. Van der Auwera, J. Klastersky, H. Lagast, and M. Husson, “Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 30, no. 1, pp. 122–126, 1986. View at Google Scholar · View at Scopus
  30. F. D. Pien and K. L. Vosti, “Variation in performance of the serum bactericidal test,” Antimicrobial Agents and Chemotherapy, vol. 6, no. 3, pp. 330–333, 1974. View at Google Scholar · View at Scopus
  31. D. L. Coleman, R. I. Horwitz, and V. T. Andriole, “Association between serum inhibitory and bactericidal concentrations and therapeutic outcome in bacterial endocarditis,” The American Journal of Medicine, vol. 73, no. 2, pp. 260–267, 1982. View at Google Scholar · View at Scopus